Drugs / SY-5609
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04929223 | Oct 2021 → Aug 2030 expected | colorectal cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1 | NCT04247126 | Jan 2020 → Jan 2023 | breast cancer, malignant pancreatic neoplasm, small cell lung carcinoma | Syros Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SY 5609 | “A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors” NCT04247126 ↗ |
| Action | Inhibit | “potent inhibition of CDK7 in cells” PMID 34726887 ↗ Nov 2021 |
| Modality | Small molecule | — CHEMBL5090754 ↗ |
| Route | Oral | “An oral CDK7 Inhibitor” NCT04247126 ↗ |
| Target | CDK7 | “inhibitor of CDK7” PMID 34726887 ↗ Nov 2021 |